Table 3.

Maximal endocrine therapy: effect of prior endocrine therapy

	SoFEAa	FACTb	SWOG 0226c
Design [F = fulvestrant (250 mg with loading dose); A = anastrozole; E = exemestane]	F + A vs F (vs E)	F + A vs A	F + A vs A
HP for PFS or TTP	1.00	0.99	0.81
Prior anti-oestrogen	− 70%	− 67%	− 40%

HR hazard ratio, PFS progression-free survival, TTP time to progression

^aJohnston et al. [33]

^bBergh et al. [34]

^cMehta et al. [35]